High Efficiency Cell Engineering Seminar at the University of Cologne, Germany

In cooperation with


Join us at the University of Cologne for an insightful seminar: 

CRISPR Engineering of Primary T cells for Autologous Cell Therapy Based on MaxCyte's Electroporation Platform

Tuesday, June 4, 2024
12:00 pm - 1:30 pm (GMT)

In-Person Event
University of Cologne
Center for Molecular Medicine Cologne
Main Seminar Room
Robert-Koch-Straße 21
50931 Köln, Germany

About the seminar

Join us for an exciting cell engineering seminar on Tuesday, June 4, from 12:00 - 1:30 pm at the University of Cologne!

Register to hear how guest speaker Dr. Hyatt Balke-Want from the Center for Molecular Medicine Cologne and previously at Stanford University's Cell Therapy Center leverages the MaxCyte platform to manufacture gene engineered products for patients. You will also gain valuable insights into how MaxCyte innovative electroporation platforms enable the efficient engineering of primary cells, stem cells, and many more cell lines. Discover how our technology guarantees high cell viability and optimal recovery rates for a wide range of applications, including CRISPR and cell therapy manufacturing.

During this seminar you will learn:

  • Chimeric Antigen Receptor (CAR) Knockins in T cells mediated by HDR or HITI
  • Preclinical data for new CAR-T cell therapies for various malignancies
  • Scalable and GMP-compliant electroporation for clinical-grade manufacturing of CAR-T cells
  • Basics about the MaxCyte electroporation process and use for various applications from basic science up to clinical manufacturing

Refreshments & Snacks on Us: We value your time, and to keep the focus on learning, we're providing complimentary snacks & refreshments for all in-person attendees.

Space is limited so reserve your spot today!


Hyatt Balke-Want

Hyatt Balke-Want, MD

Junior Research Group Leader
CMMC and Klinik I für Innere Medizin, Universitätsklinikum Köln

Dr. Hyatt Balke-Want is a Junior Research Group Leader from the University of Cologne, who just returned from his postdoc at Stanford with Crystal Mackall and Steven Feldman at the Center for Cancer Cell Therapy, Stanford, whom he joined in 2020. Prior to his postdoc at Stanford, Hyatt has been a resident in Internal Medicine and Hematology/Oncology with Michael Hallek (University Hospital Cologne) since 2015 and took care of the very first lymphoma patients treated with CAR-T cells in Germany. During his postdoc Hyatt has focused on developing a CRISPR knock-in based platform to manufacture non-viral CAR-T cells with the ultimate goal to increase accessibility for patients to CAR-T cell therapies with enhanced function.
Miguel Jimenez

Miguel Jimenez

Business Development Manager
MaxCyte, Inc.

Miguel Jimenez is the MaxCyte Sales Manager for Germany since 2018 and is based near Munich. Miguel studied Biology and graduated at University of Freiburg (Germany) followed by a PhD at Technical University Munich. For the past 23 years, Miguel held sales positions in various companies (Genetix, IntelliCyt, Sartorius) offering instrumentation in the fields of antibody development and manufacturing but also for cell-based assays and immuno-oncology.

Register today

Registration for this seminar has now closed.